STTK

4.4502.20%
HM

Helen Marie Boudreau

Independent Director

Ms. Helen Marie Boudreau, MBA, is an Independent Director of Cara Therapeutics, Inc. since August 02, 2023. She serves as an Independent Director of Rallybio LLC since September 2020. Ms. Boudreau has been Independent Director at Rallybio Corporation since September 2020. She serves as Managing Director at Estuary Ventures LLC. Ms. Boudreau serves as Independent Director of Shattuck Labs, Inc. since July 2020. Ms. Boudreau had been an Independent Director of Evaxion Biotech A/S since June 2020 until May 25, 2021. She has experiences across biotech, pharma, consulting and banking. Ms. Boudreau served as Chief Financial Officer and Treasurer at Protesostasis Therapeutics, Inc. from July 2017 to June 1, 2018. Most recently, from June 2018 to June 2019, Ms. Boudreau was Chief Operating Officer for the Bill & Melinda Gates Medical Research Institute. Ms. Boudreau served as a Director of Reunion Neuroscience Inc. (formerly known as Field Trip Health Ltd.) since April 2020. Over the course of her career, she held positions of increasing scope and responsibility in finance in the biotech and pharmaceutical industries, including Chief Financial Officer of Proteostasis Therapeutics from July 2017 to June 2018. She served as Director at Proteostasis Therapeutics, Inc. from February 2016 to July 2017. Ms. Boudreau served as the Chief Financial Officer of FORMA Therapeutics, Inc. since October 2014 until June 2, 2017. She has executive leadership experience in finance, corporate strategy, global commercial operations and R&D portfolio management. Ms. Boudreau joined Forma with global experience in finance, strategy and operations within the pharmaceutical, commercial banking and consumer sectors. Ms. Boudreau was responsible for US Treasury, Tax and Risk Management operations, financial management for all corporate entities, as well as Investor Relations for US and Canada at Novartis. She joined Novartis in 2008 as Vice President, Investor Relations and was the Global Chief Financial Officer for Novartis Oncology, where she was responsible for Finance, IT, Strategic Sourcing and Innovation, Quality and Productivity until January 2012. Ms. Boudreau spent at Novartis and Pfizer in progressively senior finance and strategy roles and worked earlier in her career at McKinsey & Company and Bank of America. From September 2008 to September 2014, Ms. Boudreau worked at Novartis Corporation, the U. S. corporate arm of Novartis AG, including served as the Chief Financial Officer of Novartis Corporation from November 2012 to September 2014, Vice President of Investor Relations from January 2012 to December 2012 and Vice President and Chief Financial Officer for Novartis Oncology from September 2008 to January 2012. She was responsible for North America. Prior to joining Novartis, she spent at Pfizer Inc., where she served as Vice President, Finance for the Customer Business Unit and Commercial Operations. She was Vice President of Finance, Global Research and Development and the Senior Director of Financial Planning and Analysis at Pfizer, Inc. Previously at Pfizer, she spent in R&D in roles of increasing responsibility for Global R&D Finance, Research Finance and Procurement, Financial Planning & Strategic Analysis and Strategic Management. She has contributed to successful product launches, driven sales growth and increased profitability, integrated mergers & acquisitions and provided leadership across Finance, IT, HR, Strategic Sourcing, Facilities and Innovation, Quality and Process improvement. She also worked in Strategic Planning in the restaurant division of PepsiCo/um! Brands, Inc. and as an Engagement Manager and Consultant at McKinsey & Company, Inc. and Bank of America Corporation. She started her career in commercial and retail banking at Bank of America. She had been an Independent Director of Premier, Inc. since June 1, 2020 until November 25, 2025. She was a Director of Protesostasis Therapeutics, Inc., since February 10, 2016 until July 2017. She is a NACD Directorship CertifiedTM by the National Association of Corporate Directors. She has a BA in Economics, summa cum laude from the University of Maryland in 1987 and an MBA with honors from the Darden Graduate School of Business at the University of Virginia in 1993.

Positions